EXEL

$70.091.01%0.70

After Hours: 70.13+0.04 +0.06%

Exelixis Inc (EXEL)

Date: O: H: L: C: Vol:

Exelixis Inc stock is traded at $70.09, with a volume of 4,636,551. It is up +1.01% in the last 24 hours and up +20.04% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Previous Close:

$69.39

Open:

$69.53

24h Volume:

4,636,551

Relative Volume:

1.81

Market Cap:

$17.10B

Revenue:

$2.38B

Net Income/Loss:

$833.42M

P/E Ratio:

23.23

EPS:

$3.02

Net Cash Flow:

$917.69M

1W Performance:

+7.65%

1M Performance:

+20.04%

6M Performance:

+60.46%

1Y Performance:

+81.25%

1-Day Range:

$69.15$72.01

1-Week Range:

$64.39$72.10

52-Week Range:

$36.00$72.10

Exelixis Inc Stock (EXEL) Company Profile

Name

Exelixis Inc

Sector

Healthcare

Industry

Biotechnology

Phone

(650) 837-7000

Address

1851 HARBOR BAY PARKWAY, ALAMEDA, CA, USA

Employee

1,077

@exelixisinc

Next Earnings Date

null

Latest SEC Filings

SEC

EXEL's Discussions on X

Compare EXEL vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXEL Exelixis Inc	$17.10B	$2.32B	$782.57M	$1.17B	$3.02
VRTX Vertex Pharmaceuticals Inc	$140.94B	$12.59B	$4.41B	$3.80B	$16.87
REGN Regeneron Pharmaceuticals Inc	$99.46B	$16.90B	$4.82B	$3.83B	$41.04
MRNA Moderna Inc	$88.17B	$2.23B	-$3.15B	-$1.24B	-$8.15
ARGX Argen X Se Adr	$55.03B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$40.86B	$6.13B	$655.71M	$1.33B	$4.48

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-26	Initiated	BMO Capital Markets	Market Perform
Aug-06-26	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-25-26	Resumed	Truist	Hold
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform
Sep-19-25	Resumed	Barclays	Equal Weight
Sep-17-25	Resumed	Barclays	Equal Weight
Sep-17-25	Initiated	Goldman	Buy
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform
Sep-19-24	Initiated	UBS	Neutral
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-23	Initiated	BTIG Research	Buy
Dec-15-23	Initiated	Citigroup	Buy
Sep-26-23	Initiated	H.C. Wainwright	Buy
Aug-22-23	Reiterated	Oppenheimer	Outperform
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight
May-10-23	Resumed	Piper Sandler	Overweight
Mar-09-23	Initiated	Wells Fargo	Overweight
Jan-26-23	Initiated	Credit Suisse	Outperform
Oct-18-22	Initiated	JMP Securities	Mkt Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-03-21	Resumed	Jefferies	Buy
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Reiterated	H.C. Wainwright	Buy
Jun-15-21	Initiated	H.C. Wainwright	Buy
May-18-21	Resumed	Goldman	Sell
Mar-31-21	Initiated	Credit Suisse	Outperform
Mar-12-21	Initiated	Wolfe Research	Outperform
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Nov-13-19	Initiated	BofA/Merrill	Buy
Mar-18-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-17-18	Initiated	Goldman	Neutral
Sep-10-18	Initiated	Morgan Stanley	Underweight
May-11-18	Reiterated	Needham	Buy
Oct-17-17	Reiterated	Needham	Buy
Oct-17-17	Reiterated	RBC Capital Mkts	Outperform
Oct-16-17	Reiterated	SunTrust	Buy
Sep-22-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-12-17	Reiterated	Needham	Buy
Jul-14-17	Initiated	SunTrust	Buy
Mar-31-17	Initiated	Needham	Buy
Mar-16-17	Initiated	Oppenheimer	Perform
Feb-28-17	Downgrade	Stifel	Buy → Hold
Nov-03-16	Initiated	Deutsche Bank	Buy
Oct-10-16	Upgrade	Piper Jaffray	Neutral → Overweight
Sep-15-16	Reiterated	Stifel	Buy

Exelixis Inc Stock (EXEL) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2026-01-02	2025-01-03	2023-12-29	2022-12-30	2021-12-31
Revenue USD (M)	2,320.13	2,168.70	1,830.21	1,611.06	987.54
Cost of revenue USD (M)	83.70	76.22	72.55	57.91	36.27
Gross profit USD (M)	-	-	1,757.66	1,553.15	951.27
Research and development USD (M)	825.00	910.41	1,044.07	891.81	547.85
Operating expenses USD (M)	1,447.94	1,564.08	1,586.78	1,351.67	841.21
Operating income USD (M)	872.19	604.62	170.89	201.48	110.06
Income before tax USD (M)	-	-	170.89	201.48	130.84
Income tax expense USD (M)	158.64	160.37	49.76	52.07	19.06
Net income USD (M)	782.57	521.27	207.77	182.28	111.78
Basic EPS USD/shares	2.88	1.80	0.65	0.57	0.36
Diluted EPS USD/shares	2.78	1.76	0.65	0.56	0.35
Basic weighted shares shares (M)	271.57	290.03	318.15	321.53	308.27
Diluted weighted shares shares (M)	281.86	296.13	321.46	324.56	318.00
Selling, general and administrative USD (M)	518.73	492.13	542.71	459.86	293.36

Exelixis Inc Stock (EXEL) Insider Trading

Beckerle Mary CAug 10 '26
Director
Transaction
Sale
Cost
$53.66
#Shares
9,812
Value ($)
526,512
#Shares Total
16,079
MARY BECKERLEAug 10 '26
Director
Transaction
Proposed Sale
Cost
$53.66
#Shares
9,812
Value ($)
526,496
#Shares Total
0
JACK L WYSZOMIERSKIJun 01 '26
Director
Transaction
Proposed Sale
Cost
$50.55
#Shares
3,925
Value ($)
198,409
#Shares Total
0
Eckhardt Sue GailJun 01 '26
Director
Transaction
Proposed Sale
Cost
$50.87
#Shares
9,812
Value ($)
499,136
#Shares Total
0
Eckhardt Sue GailJun 01 '26
Director
Transaction
Sale
Cost
$50.14
#Shares
9,812
Value ($)
491,974
#Shares Total
16,079
WYSZOMIERSKI JACK LJun 01 '26
Director
Transaction
Sale
Cost
$50.55
#Shares
3,925
Value ($)
198,409
#Shares Total
284,384
Aftab DanaMay 26 '26
EVP, Research and Development
Transaction
Sale
Cost
$50.35
#Shares
43,451
Value ($)
2,187,758
#Shares Total
594,741
DANA T AFTABMay 26 '26
Officer
Transaction
Proposed Sale
Cost
$50.35
#Shares
43,451
Value ($)
2,187,758
#Shares Total
0
PATRICK JOSEPH HALEYMay 20 '26
Officer
Transaction
Proposed Sale
Cost
$49.81
#Shares
32,110
Value ($)
1,599,444
#Shares Total
0
Haley Patrick J.May 20 '26
EVP, Commercial
Transaction
Sale
Cost
$49.81
#Shares
32,110
Value ($)
1,599,399
#Shares Total
357,638

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Beckerle Mary C	Director	Aug 10 '26	Sale	$53.66	9,812	526,512	16,079
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	$53.66	9,812	526,496	0
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	$50.55	3,925	198,409	0
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	$50.87	9,812	499,136	0
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	$50.14	9,812	491,974	16,079
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	$50.55	3,925	198,409	284,384
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	$50.35	43,451	2,187,758	594,741
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	$50.35	43,451	2,187,758	0
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	$49.81	32,110	1,599,444	0
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	$49.81	32,110	1,599,399	357,638

Exelixis Inc Stock (EXEL) Latest News

Oct 30, 2026

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

Oct 28, 2026

Oct 27, 2026

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026

Oct 24, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 22, 2026